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However, identifying candidates for this aggressive sur-
gical approach is controversial because the tumor and
host factors that allow systemic disease to be controlled
with local therapy are unknown. Therefore the purpos-
es of this study were (1) to evaluate the efficacy of
resection of both hepatic and pulmonary colorectal
metastases, (2) to investigate the influence of the
sequence and timing of metastases, and (3) to identify
the profile of patients most likely to benefit from both
hepatic and pulmonary metastasectomies. 
Patients and methods
Patient groups. Forty-eight patients at The Cleveland Clinic
Foundation with resected colorectal carcinoma and only hepat-
ic and pulmonary metastases were identified. During this time
period, 5787 patients had resections of primary colorectal car-
cinomas; 466 patients had resections of isolated colorectal
hepatic metastases; and 72 patients had resections of isolated
pulmonary metastases. The selection of patients for resection
was not by formal protocol but by clinical evaluation.
C onventional management of stage IV colorectal car-cinoma in most patients is palliative. However,
chemotherapy, the mainstay in the treatment of systemic
disease, seldom produces long-term survival. In an occa-
sional patient with metastatic disease that is confined to
the liver or lung, metastasectomy may be curative. 
Metastasectomy in some patients with colorectal
metastases to both liver and lung has been reported.1-7
Background: Conventional management of stage IV colorectal carcinoma
is palliative. The value of resecting both liver and lung colorectal metas-
tases that occur in isolation of other sites of metastasis is undetermined.
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Resection group. From the prospective pathologic data-
base and subsequent review of medical records of patients
undergoing resection of colorectal carcinoma between March
1979 and March 1998, 25 patients were identified who had
had resection of both hepatic and pulmonary metastasec-
tomies and had no evidence at that time of metastases to other
organs.
Nonresection group. From the prospective tumor registry
begun in 1986 and subsequent review of medical records, 23
patients were identified through 1996 with resected colorec-
tal carcinoma who had both hepatic and pulmonary metas-
tases, had not undergone both hepatic and pulmonary metas-
tasectomies, and had no evidence at the time of metastases to
other organs. 
Comparison of groups. Categoric variables within each
group were summarized by number and percent of patients in
each category. Continuous variables within each group were
summarized by mean, standard deviation, median, minimum,
and maximum. Differences between the resection and nonre-
section groups were compared with the c 2 test for categoric
variables and the t test for continuous variables, adjusted,
when appropriate, for unequal variances.
Benefits of metastasectomy
End point. The end point for the assessment of efficacy was
death. Vital status was available in the respective databases.
For patients alive when their medical records were retrieved,
telephone interviews were conducted to update vital status.
No patient was lost to follow-up. 
Comparison of survival. Two versions of follow-up were
used in the analysis of survival: (1) from colorectal resection
to last follow-up (first cancer resection) and (2) from last
resection or appearance of metastases to last follow-up (last
metastatic appearance). The latter is the time at which all
patients were first known to have metastases to both liver and
lung.
For both versions, nonparametric estimates of survival
were obtained by the Kaplan-Meier method, separately for
the resection group, the nonresection group, and the com-
bined groups.8 Univariable comparisons between the groups
were evaluated by the log-rank test. For the second version, a
parametric method was used to resolve the number of hazard
phases, identify the shape of the hazard function, and esti-
mate its parameters.9
Fig 1. Survival after the last appearance or resection of metastases in the resection and nonresection groups. Each
symbol represents a death, positioned according to Kaplan-Meier nonparametric estimates with vertical bars
equivalent to 1 SE. The solid lines are parametric survival estimates enclosed within confidence intervals (dashed
lines) equivalent to 1 SE. The numbers of patients living and being followed up are shown in parentheses.
Table I. Timing and sequence of pulmonary and
hepatic metastases in relation to colorectal cancer
resection
Resection Nonresection 
Timing and sequence 
(n = 25) (n = 23)
of metastases n % n %
Synchronous* 2 8 21 91
Metachronous 17 68 0 0
Colonfi liverfi lung 12 48 0 0
Colonfi lungfi liver 5 20 0 0
Mixed 6 24 2 9
Colon and lungfi liver 1 4 1 4
Colon and liverfi lung 5 20 1 4
*P < .001, c 2 test.
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Timing and sequence of metastases
Timing. Appearance of hepatic and pulmonary metastases
was defined as either synchronous (both hepatic and pul-
monary metastases identified within 3 months of colon resec-
tion), metachronous (the primary disease and each metastatic
site identified separately with more than 3 months between
each of the 3 appearances), or mixed (the primary and one
metastatic site identified synchronously and the second
metastatic site appeared more than 3 months later). 
Influence of timing. The influence of timing of the appear-
ance of metastases was assessed in 2 ways. First, survival
after the first cancer resection was used to assess whether
longevity was different for synchronous, mixed, or metachro-
nous metastases. However, survival assessed in this fashion is
potentially biased upward because patients with nonsynchro-
nous metastases must survive long enough for the sequence
of metastases to become manifest. Therefore when the sec-
ond version of survival was used (time 0 being the time when
all metastases were diagnosed), variables were entered into
the analysis to account for the intervals between the colorec-
tal cancer resection and the appearance of the metastases.
Influence of sequence. In the multivariable analyses, from
Fig 2. Instantaneous risk of death (hazard function) after last appearance or resection of metastases for resection
and nonresection groups.
Table II. Intervals between colorectal cancer resection and appearance or resection of metastases
Timing (mo)
Group N Mean SD Median Range P value*
All cases
Colorectal to liver metastasis Resection 25 17.0 17.6 9 0-66 <.001
Nonresection 23 0.8 2.9 0 0-13 —†
Colorectal to lung metastasis Resection 25 27.2 23.4 18 1-88 <.001
Nonresection 23 0.6 1.7 0 0-8 —†
Metachronous cases
Colorectal cancer to first metastasis Resection 17 19.6 12.1 18 4-43 —
Nonresection 0 — — — —
Colorectal cancer to second metastasis Resection 17 39.1 23.4 37 7-88 —
Nonresection 0 — — — —
Second metastasis to third metastasis Resection 17 19.5 16.5 13 1-53 —
Nonresection 0 — — — —
Mixed cases
Mixed metastases to second metastasis Resection 6 16.6 14.9 11 5-44 .6
Nonresection 2 10.8 4.1 11 8-14
*t Test.
†Cochran and Cox adjustment to the t test (unequal variances).
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the time of last appearance of metastases, variables were
assessed that identified the order in which metastases
appeared (both together, liver then lung, lung then liver).
The ideal patient for metastasectomy. Patient character-
istics that increased or decreased the risk of death were iden-
tified by multivariable analyses.
Study variables. The following variables were entered
into the multivariable analyses: age, gender, site of colorec-
tal primary (right, a primary carcinoma originating proximal
to the midtransverse colon; left, a primary carcinoma origi-
nating distal to the midtransverse colon including the rec-
tum), TNM stage of the primary colorectal carcinoma, date
of colorectal resection, adjuvant therapy after colorectal
resection, sequence and timing of metastases, number of
hepatic metastases, date of appearance or resection of hepatic
metastases, number of pulmonary metastases, unilateral or
bilateral pulmonary metastases, date of appearance or re-
section of pulmonary metastases, follow-up date, and vital
status.
Multivariable analyses
GENERAL CONDUCT OF THE MULTIVARIABLE ANALYSES. Ex-
ploratory analysis included correlation analysis, stratified
Fig 3. Survival in the resection group after the last resection of the metastases, stratified according to the timing
of the metastases: synchronous, metachronous, or mixed.
Fig 4. Survival in the resection group as in Fig 3, except the synchronous and mixed subgroups are combined.
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Fig 5. Predicted 5-year survival after the resection of the last metastasis, according to the interval between the
colorectal cancer diagnosis and the resection and the appearance of the lung metastasis. The survival estimates
(solid line) are enclosed within confidence limits (dashed line) equivalent to 1 SE.
Table III. Comparison of resection and nonresection patients
Resection (25) Nonresection (23)
Variable/responses n % n % P value*
Demographic data
Gender
Female 16 64 8 35 .04
Male 9 36 15 65
Colorectal cancer
TNM stage
I 1 4 0 0 <.001
II 6 24 1 4
III 10 40 1 4
IV 8 32 21 91
Type of colorectal cancer
Left 22 88 11 48 .003
Right 3 12 12 52
Chemotherapy after colorectal operation
Yes 13 52 9 39 .4
No 12 48 14 61
Liver metastases
Liver metastases (No.)
Single 15 60 3 13 <.001
Multiple 10 40 20 87
Lung metastases
Unilateral 17 68 6 26 .004
Bilateral 8 32 17 74
Lung metastases (No.)
Single 10 40 3 13 .036
Multiple 15 60 20 87
* c 2 test.
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life-table analyses, and decile risk analysis of ordinal and
continuous variables to determine possible transformations of
scale. A directed technique of stepwise entry of variables into
the multivariable risk factor model was then used.10 The P
value criterion for retention of variables in the models was .1.
Separate analyses were performed for the resection patients,
the nonresection patients, and the combined group, which
included group interaction terms. Regression coefficients are
presented ± 1SE.
SPECIFIC TYPES OF MULTIVARIABLE ANALYSES. Three types of
multivariable analyses were conducted to identify risk factors
for death: (1) Cox semiparametric proportional hazards
regression,11 (2) parametric hazard function regression,9 and
(3) bootstrap hazard function regression. The bootstrap haz-
ard function regression was used to verify the other multi-
variable analyses; in this analysis, automated forward risk-
factor selection was performed on 1000 data sets, each
consisting of a 5-time resampling of the original data set.
Fig 6. Survival after the appearance or resection of the metastasis in patients with a solitary liver metastasis, strat-
ified according to resection and nonresection. (See Fig 1 for further explanation.)
Fig 7. Survival after the appearance or resection of metastasis in patients who had multiple liver metastases, strat-
ified according to resection and nonresection. (See Fig 1 for further explanation.)
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These were summarized in terms of the frequency of selec-
tion of risk factors.12
NATURE AND INFLUENCE OF RISK FACTORS. Exploration of the
influence of risk factors in the parametric multivariable
analysis was performed by constructing a nomogram that
represented the solution of the parametric equation for spe-
cific supplied values of each factor.
Results
Benefit of metastasectomy
Survival. Survival was longer in the resection group
than in the nonresection group, whether calculated from
first colorectal resection (first resection) or last appear-
ance or resection of metastases (last metastasis).
Median survival after the first colorectal cancer resec-
tion was 47 months in the resection group and 7 months
in the nonresection group; 5-year survival was 43% and
0% (P < .001). Median survival after the last appear-
ance of metastases was 16 months in the resection
group and 6 months in the nonresection group; 5-year
survival was 9% and 0% (P < .001; Fig 1).
Time-related risk. When assessed from the time of
last appearance of metastases, time-related instanta-
neous risk of death (hazard function) for resection and
Table IV. Relationship of individual variables to death (Cox proportional hazards method)
95% Confidence 
Variable/responses P value Hazard ratio limit
Nonresection vs resection <.001 3.40 1.78–6.50
Male vs female .2 1.52 0.83–2.78
Age (y) at colorectal operation (per 10-y increase) .02 1.52 1.08–2.13
Colorectal cancer
TNM stage
III vs I-II .4 0.67 0.25–1.81
IV vs I-II .5 1.33 0.60–2.94
Type of colorectal cancer (left vs right) .6 0.85 0.44–1.63
Chemotherapy after colorectal operation (yes vs no) .7 0.90 0.49–1.66
Timing of colon cancer and metastatectomy
Mixed/synchronous vs metachronous <.001 3.33 1.64–6.75
Mixed vs metachronous .1 2.35 0.94–5.88
Synchronous vs metachronous <.001 4.01 1.89–8.50
Liver metastases
No. of liver metastases (multiple vs single) <.001 3.37 1.72–6.61
Interval from colorectal cancer to liver cancer (per 1-mo increase) .02 0.97 0.95–0.99
Lung metastases
Bilateral vs unilateral .7 1.15 0.63–2.11
No. of lung metastases (multiple vs single) .1 1.77 0.87–3.60
Interval from colorectal cancer to lung cancer (per 1-mo increase) <.001 0.97 0.95–0.98
Table V. Risk factors for death after the appearance of both hepatic and pulmonary metastases (Cox proportional
hazards method; n = 48)
95% Confidence 
Variable/responses P value Hazard ratio limit
Model 1
Age (y) at colorectal operation (per 10-y increase) .028 1.48 1.05-2.11
No. of liver metastases (multiple vs single) <.001 3.47 1.67-7.20
Group (nonresection vs resection) .013 2.47 1.21-5.03
Model 2
Age (y) at colorectal operation (per 10-y increase) .021 1.54 1.07-2.22
No. of liver metastases (multiple vs single) .006 2.74 1.33-5.63
Interval from colorectal cancer to lung cancer (per 1-mo increase) .011 0.97 0.96-0.99
Model 3
Age (y) at colorectal operation (per 10-y increase) .013 1.56 1.10-2.22
No. of liver metastases (multiple vs single) .001 3.27 1.59-6.74
Timing of metastases (synchronous/mixed vs metachronous) .031 2.27 1.08-4.79
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nonresection groups differed (Fig 2). For the resection
group, the risk of death increased from last resection,
peaked at 2 years, and declined thereafter. In contrast,
the nonresection group’s risk of death was both con-
stant across time and systematically higher (nonover-
lapping confidence limits; P < .001).
Timing and sequence of metastases. The timing
and sequence of hepatic and pulmonary metastases dif-
fered in the resection and nonresection groups (Tables
I and II). Synchronous disease was present at diagnosis
in only 2 patients in the resection group and in all but 2
patients in the nonresection group.
In the resection group, patients with metachronous
resections survived longer (median survival, 70
months) than patients with synchronous resections
(median survival, 22 months) or those patients with
mixed resections (median survival, 31 months) when
calculated from first cancer resection (P < .001).
However, in this group, survival was similar when
calculated from the time of last metastatic resection;
median survival was 22 months for metachronous
resections, 14 months for synchronous resections, and
12 months for mixed resections (P = .21; Fig 3). When
synchronous and mixed resection groups were com-
bined, survival was also similar; median survival was
22 months for metachronous resections and 14 months
for combined resections (P = .09; Fig 4).
The favorable influence of metachronous appearance
of metastases was confirmed by multivariable analyses
of death after the last metastasis resection. The only
correlate found was the favorable influence of a longer
interval between the colorectal cancer diagnosis and
the development of pulmonary metastases (P = .005).
The influence and shape of a longer interval on 5-year
survival is shown in Fig 5.
The number of patients with metachronous lesions in
the nonresection group was too small to make mean-
Fig 8. Predicted 5-year survival after the resection of the last metastasis, according to age at colorectal cancer
diagnosis and resection. Two sets of estimates are shown that are solutions to the multivariable equation for death.
The first is for a patient with a long (4 years) disease-free interval (from colorectal cancer to resection of pul-
monary metastases) and the second is for a patient with a short (6 months) interval. 
Table VI. Risk factors for death after the appearance
of both hepatic and pulmonary metastases (parametric
hazard function method; n = 48)
Risk factors for death Coefficient ± SD P value
Model 1*
Longer interval to development –0.28 ± 0.124 .02
of pulmonary metastases (y)
Multiple hepatic metastases 1.58 ± 0.45 .0004
Resection group –0.97 ± 0.45 .03
Intercept 1.93
Model 2†
Longer interval to development 
of pulmonary metastases (y) –0.32 ± 0.124 .01
Multiple hepatic metastases 1.13 ± 0.37 .002
Older age at diagnosis 0.037 ± 0.0182 .04
Intercept 0.154
*Shaping parameter estimates: d = 0; r = 5.73; n = –0.670; m = 0.
†Shaping parameter estimates: d = 0; r = 7.64; n = –0.704; m = 0.
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ingful conclusions about timing and sequence of
metastases.
The ideal patient for metastasectomy. Patients
undergoing resections for liver and lung metastases
were younger than those not undergoing resection. Age
at the diagnosis of colorectal cancer in the resection
group was 56 ± 10 years (median, 57 years; range,
37–72 years) and 61 ± 8 years in the nonresection
group (median, 62 years; range, 46–77 years; P = .04).
Patients who underwent resection were more likely to
be women, to have a less advanced and left-sided col-
orectal cancer at the time of diagnosis, and to have soli-
tary liver and lung metastases (Table III).
In the nonresection group, the 3 patients with solitary
liver metastases fared equally well as their counterparts
in the resection group (Fig 6). 
The presence of multiple liver metastases was the
only risk factor identified for death in the nonresection
group (P = .02). Survival was poor in patients with
multiple liver metastases, but better in the resection
group (Fig 7).
A number of variables were correlates of either poor-
er or longer survival from the appearance of the last
metastasis, and many variables were correlated one
with another (Table IV). Thus the multivariable analy-
sis of the combined groups produced more than one
equivalent model by all 3 methods of analyses, all con-
sistent with the data (Tables V and VI). These analyses
identified the younger patients at diagnosis of colorec-
tal cancer (Fig 8), with a solitary liver metastasis,
metachronous disease with a long disease-free interval,
and resection of both liver and lung metastases as those
more likely to enjoy long-term survival and possibly
cure (Fig 9).
Discussion
Benefit of metastasectomy. More than 50% of
patients undergoing curative resection of a colorectal
carcinoma will experience recurrent disease. Liver and
lung are the most common sites of distant metastases.
On occasion, a patient will have metastases limited to
the liver and lung after a curative colon resection.
Inherently, these patients represent a highly select
group. Does resection of metastases improve survival
in these patients or is this a group of patients who will
have a good survival regardless of treatment?13 The rar-
ity of these patients and the ethics of withholding
resection in an ideal surgical candidate preclude a
phase III study comparing surgical to nonsurgical care.
This study was developed to illuminate the controversy
of resection of liver and lung metastases after colorec-
tal resection. It can be debated that the 2 groups of
patients are not comparable. However, the important
differences observed between the resection and nonre-
section groups provide valuable insight into the selec-
tion process.
Fig 9. Survival after the resection of the last metastasis in a patient with ideal characteristics for resection (age,
50 years; solitary liver metastasis; 4-year interval from colorectal cancer resection to pulmonary metastasis), con-
trasted with a patient with nonideal characteristics for resection (age, 70 years; multiple liver metastases; syn-
chronous disease). 
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The benefit of resection can be best understood by
the evaluation of the hazard functions of the 2 groups.
For the nonresection group, the risk of death is con-
stant. In contrast, the biphasic hazard function of the
resection group illustrates the benefit of resection. If
the resection group was comprised of a poor-risk group
who rapidly die of the disease and a good-risk group
who have prolonged survival despite treatment, the
hazard function would be that of an exponential decay
from the risk of nonresection group to the risk of the
resection group. However, for the resection group, the
risk of death after resection slowly rises to a peak at 2
years. Surprisingly, the risk falls to a level similar to
that of early postoperative risk and is persuasive evi-
dence that, despite selection, resection provides a sur-
vival advantage.
Timing and sequence of metastases. The timing of
metastases greatly influences survival. Metachronous
metastases provide an intrinsic survival advantage.
These patients must survive the resection of the col-
orectal primary and, after a disease-free interval, under-
go resection of the first metastatic site. After a second
disease free-interval, metastasectomy is performed at
the second site. If survival is calculated from the col-
orectal resection or the first metastasectomy, a patient
with metachronous metastases will almost always have
better survival. However, if the date of last resection
(the time at which the patient is rendered cancer free) is
chosen for the calculation of survival, the timing of
metastases is no longer a factor that influences survival.
The sequence of metastases also influenced survival.
Most patients with metachronous or mixed disease had
a sequence of metastases to the liver and then the lung.
Patients with synchronous disease or metastases to the
lung and then the liver had a poor survival. This implies
that the route of metastases is crucial for patients to ben-
efit from resection of both liver and lung metastases.
Patients with cascade metastases from the colorectal
primary through the portal venous system to the liver
and then through the systemic venous system to the lung
are most likely to have a metachronous pattern of metas-
tases. Patients with simultaneous metastases via the por-
tal venous system to the liver and the systemic venous
system to the lung have a reduced survival.
The ideal patient for metastasectomy. Selection of
patients for resection of hepatic and pulmonary metas-
tases is an important factor that determines survival.
Unfortunately, the tumor and host factors that allow
local resection to control systemic disease are unknown.
Multivariable analyses were used to adjust for important
differences between and within the groups. Although
not an adequate substitute for a randomized trial, it clar-
ifies which patients are more likely to benefit from
resection. Despite the limitations of a small study
group, valuable information has been learned to assist in
the selection and management of these patients. 
Conclusions
In select patients with colorectal cancer, resection of
metachronous solitary liver and lung metastases
improves survival and may result in cure. Resection of
multiple synchronous metastases may provide longer
palliation than conventional therapy.
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Discussion
Dr Mark S. Allen (Rochester, Minn). Since Alfred Blalock
first reported on pulmonary metastasectomy for colorectal
metastases in 1944, many centers, including our own, have
reported their results. Unfortunately, all of these results, as is
the current one, are retrospective. They are all unable to
answer the question that a randomized trial could: Is it bene-
ficial to resect metastatic disease? 
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We in the surgical community have come to accept metas-
tectomy as a beneficial technique, but there are those in the
medical field who still question the efficacy of this procedure.
Ethically, it is nearly impossible to carry out such a prospec-
tive trial. Thus we are left with retrospective reviews, such as
this one. This does not mean that these reviews are not use-
ful. Quite the contrary. When properly done, they can provide
us with information about factors that lead to improved sur-
vival in selected groups of patients. 
Several authors have reported a number of factors, includ-
ing age, disease-free interval, number of metastases, and low
carcinogenic embryonic antigen level, which impart and
improve survival. In this article, the authors have performed
a careful and complete statistical analysis of a relatively small
group of patients who have undergone resection of both
hepatic and pulmonary metastases. They attempt to draw a
conclusion between a group of patients who underwent resec-
tion and a group who did not undergo resection. 
I would caution the audience that this comparison has lim-
ited validity because there is an obvious bias of selection in
favor of the patients having resection. The authors have
shown through multivariate analysis that patients who are
young, who have solitary hepatic metastases, who later expe-
rience pulmonary metastases, and who have a long disease-
free interval survive longer. 
First, in our paper and in others, patients with an elevated
carcinoembryonic antigen level had a worse 5-year survival
than those with a normal level. Did you observe this finding?
If so, what do you think the significance of it is? 
Second, what do you use as a criteria to turn down patients
for resection? Is there a number of nodules that is too many
to have a resection? How do you select patients for an opera-
tion, and how do you decide which ones will not undergo an
operation? 
Third, from a technical standpoint, do you perform the
operation as a combined hepatic and pulmonary resection or
do you stage it?
Dr Robinson. Thank you for your questions. Carcino-
embryonic antigen levels were not consistently measured in
these patients. Because this information was incomplete, it
was not included in the analysis.
There was no protocol for patient selection. Only clinical
evaluation and the surgeon’s judgment were used to select
patients for resection. There was no cutoff for the number of
metastases. Indeed, one patient had 7 bilateral pulmonary
metastases resected.
Only 2 patients had synchronous resections, although 23
patients had metachronous resections. Our experience is with
staged resections. This approach allows operative confirma-
tion that the first metastatic site can be resected and that there
are no unexpected metastases in the operative field. Staging
of the resections allows recovery time and a reassessment
period to assure there is no progression of metastatic disease
or recurrence at previous resection sites.
If the resections are to be synchronous, it is best to com-
plete one resection before embarking on the second. Doing
the hepatic resection first allows assessment of the primary
colorectal resection site and the abdominal cavity, common
sites of recurrence. 
Dr Larry S. Kaiser (Philadelphia, Pa). Getting back to
some of the selection factors when you went back and looked
at these charts, was age a major criteria in selecting the patients
as best as you can tell retrospectively? Can you comment on
how many of these patients would have received 5-fluo-
rouracil, which is the standard agent for the treatment of col-
orectal cancer and is used as an adjuvant? In light of the fact
that data will be presented at the American Society of Clinical
Oncology meeting that shows that CPT-11, now called irinote-
can, has been shown to be efficacious in patients whose condi-
tion did not respond to 5-fluorouracil, how would that knowl-
edge (that is, a new drug effective in a solid tumor like colon
cancer) have an impact on these types of operations?
Dr Robinson. It did not appear from the retrospective
analysis that age was a criterion for metastasectomy. If a
patient was medically fit for resection, the patient was
deemed a candidate for resection.
We did compare the survival of patients who received
chemotherapy to the survival of those patients who did not.
Equal numbers of patients in both groups received
chemotherapy, 13 of 25 patients in the resection group and 9
of 23 patients in the nonresection group. Chemotherapy did
not affect survival. The regimens were 5-fluorouracil based;
no patient received irinotecan (CPT-11). 
Dr John A. Odell (Jacksonville, Fla). Which one would
you do first, the lung or the liver metastases? My approach is
to do the liver first because there might be unsuspected peri-
toneal seedings or other spread that would prevent you from
performing the thoracic part of the procedure. Have you ever
found any of these situations where at the time of managing
the liver metastases you found that it was not indicated to
proceed with the pulmonary resection? 
Dr Robinson. In the uncommon situation of synchronous
metastases, we agree that it makes sense to do the abdominal
exploration and hepatic resection first. This confirms that
there are no unexpected local recurrences or abdominal
metastases and that the hepatic metastases are resectable. 
